Supaveda · Ingredient Spotlight
Haridra
Curcuma longa L. — The Golden Root
Also known as: Turmeric · Haldi · Kanchani · Nisha · Gauri · Rajani · Halud · Jiang Huang
Turmeric (Curcuma longa) is simultaneously one of the most ancient medicines on Earth and the most studied botanical in modern science — with over 20,000 published papers on PubMed and the distinction of being the best-selling botanical dietary supplement in the United States. That combination of ancient pedigree and modern scientific scrutiny is almost without parallel in plant medicine.
A rhizomatous perennial herb of the ginger family (Zingiberaceae), native to South and South-East Asia and cultivated across tropical regions worldwide, C. longa has been used in Ayurveda, Siddha, Unani, and Chinese medicine for over 4,000 years. Its primary bioactive compounds — the curcuminoids, led by curcumin (diferuloylmethane) — have been the subject of more than 400 clinical trials and a rapidly growing body of meta-analyses that confirm activity across inflammatory, metabolic, joint, cardiovascular, and neurological disease domains. 1 A 2025 umbrella review of intervention meta-analyses published in Frontiers in Pharmacology (PMC12176752) pooled evidence across multiple systematic reviews and confirmed significant reductions in CRP, TNF-α, and IL-6 — the three canonical markers of systemic inflammation — alongside reductions in body weight, BMI, and cholesterol. 2
🌶 The Piperine Story — How Ayurveda's Kitchen Wisdom Became Peer-Reviewed Fact
One of the most compelling validations of Ayurvedic practice by modern pharmacology concerns a culinary habit so ordinary it had been practised across India for millennia without any scientific justification: adding black pepper to turmeric preparations. In Ayurveda, the combination of turmeric with the pungent herbs collectively called Trikatu (black pepper, long pepper, and ginger) was standard formulation practice — described in classical texts as enhancing the herb's action by "kindling digestive fire" and improving absorption.
In 1998, Shoba et al. published a landmark study in Planta Medica that quantified this effect precisely: co-administration of piperine (the active alkaloid of black pepper) with curcumin increased curcumin's oral bioavailability in humans by 2,000%. 3 The mechanism — piperine inhibits glucuronidation (the liver enzyme system that rapidly inactivates curcumin) and reduces intestinal efflux — was exactly what traditional Ayurvedic formulation practice had been achieving by combining the two plants, long before either glucuronidation or efflux transporters had been described. This is not coincidence: Ayurvedic formulation science arrived at this combination through centuries of clinical observation, and the biochemistry merely explained what the tradition had already established. Today, the curcumin-piperine combination is the global standard for bioavailable turmeric supplementation, and this ancient formulation principle underlies the rationale for including black pepper in most modern clinical-grade turmeric products. 4
At a Glance — Key Evidence-Backed Benefits
Traditional Ayurvedic & Classical Uses
Turmeric is among the most extensively described medicinal plants in the classical Ayurvedic literature — appearing in the Charaka Samhita, Sushruta Samhita, Ashtanga Hridayam, and all eight major Ayurvedic Nighantus. Its Sanskrit names encode its primary therapeutic identities: Haridra (the yellow one), Kanchani (the golden one), Gauri (the brilliant), Nisha (the night — reflecting its role in skin brightening, as night lightens the complexion), and most powerfully, Vishagni — "the destroyer of poisons" — which captures its classical role as the foremost detoxifying and anti-inflammatory herb in Ayurvedic medicine. 5
In classical Siddha medicine, turmeric was classified as one of the Kaya Kalpa herbs — rejuvenatives that transform the body and confer longevity. In Chinese medicine (Jiang Huang), it was prescribed for "moving the blood" and resolving stagnation — the Chinese medicine equivalent of the Ayurvedic anti-inflammatory and circulatory-activating roles. In Unani medicine it is Zard Chob — the yellow wood — used for liver, digestion, and inflammatory conditions. The unanimity of these independent medical traditions on turmeric's core properties — anti-inflammatory, liver-protective, wound-healing, and detoxifying — is itself a form of cross-cultural clinical evidence. 1
Ayurvedic Properties (Guna)
The heating potency (Ushna Veerya) distinguishes Haridra from cooling anti-inflammatory herbs. This is pharmacologically significant: curcumin's anti-inflammatory action operates through NF-κB inhibition rather than through COX pathway cooling — a mechanism consistent with heating rather than cooling potency. High-Pitta individuals are advised to use turmeric with cooling carriers (ghee, milk, aloe vera) or in moderation.
Conditions Traditionally Treated
- Inflammation (Shotha) — the primary indication across all classical traditions; all forms of inflammatory swelling
- Skin diseases (Kushtha) — the classical foremost skin herb; complexion brightening (Varnya); acne, eczema, psoriasis, wound healing
- Liver conditions (Yakrit Vikara) — hepatoprotective; bile-stimulating; supports fat metabolism and detoxification
- Diabetes (Prameha) — blood sugar regulation; antidiabetic properties confirmed across multiple RCTs and meta-analyses
- Respiratory conditions — mucolytic; anti-inflammatory in bronchial conditions; traditionally taken with milk for respiratory Kapha
- Wounds and infections (Vrana) — topical antimicrobial; accelerates wound healing; reduces scarring
- Gastrointestinal conditions — stimulates digestive fire (Deepana); anti-ulcer; reduces intestinal inflammation; classical IBS remedy
- Joint conditions (Sandhivata) — the primary Ayurvedic herb for arthritis; reduces joint inflammation and pain
- Anaemia (Pandu) — described as a blood purifier and red blood cell tonic
- Gynecological conditions — emmenagogue; traditionally used for irregular menstruation and uterine conditions
- Detoxification (Vishagni) — classical antitoxin; blood purifier; antimicrobial
- Neurological conditions — classical brain tonic; the emerging neuroprotective and anti-Alzheimer's research directly validates this ancient classification
Key Active Compounds
The rhizome of C. longa contains over 200 bioactive compounds — a pharmacological complexity that explains why whole turmeric preparations may exhibit properties that isolated curcumin does not. The curcuminoids predominate in therapeutic activity, but the essential oils and polysaccharide fractions contribute independently confirmed anti-arthritic and anti-inflammatory effects. 6
Primary Bioactive Constituents
How Turmeric Works — Six Therapeutic Mechanisms
Curcumin's extraordinary breadth of activity derives from its ability to simultaneously modulate multiple upstream molecular targets — particularly transcription factors that control cascades of downstream genes. Unlike most pharmaceuticals designed to hit a single target, curcumin acts as what researchers describe as a "pleiotropic" compound — influencing over 250 molecular pathways across different disease domains with a single mechanism architecture. 1
Turmeric's Six Core Therapeutic Mechanisms
What the Research Says
The most comprehensive synthesis of curcumin's clinical evidence to date is the 2025 umbrella review of intervention meta-analyses published in Frontiers in Pharmacology (PMC12176752), which pooled findings from six independent meta-analyses evaluating inflammatory and oxidative stress markers across randomised controlled trials. 2
The pooled findings confirmed: significant reduction in C-reactive protein (CRP) by WMD −0.58 mg/L (95% CI: −0.74, −0.41); significant reduction in TNF-α by WMD −3.48 pg/mL (95% CI: −4.38, −2.58); significant reduction in IL-6 by WMD −1.31 pg/mL (95% CI: −1.58, −0.67) — all compared to placebo. The same review pooled three meta-analyses on anthropometric outcomes and confirmed significant reductions in body weight (WMD −0.82 kg), BMI (WMD −0.30 kg/m²), waist circumference (WMD −1.31 cm), body fat percentage (WMD −0.88%), and leptin — alongside a significant increase in adiponectin (an anti-inflammatory adipokine). CRP, TNF-α, and IL-6 are the three most widely used clinical markers of systemic inflammation. Their simultaneous significant reduction across pooled meta-analyses of RCTs represents robust clinical evidence for turmeric's anti-inflammatory classification — confirming what the Charaka Samhita's classification as Vishagni (destroyer of inflammatory "poisons") encoded thousands of years ago.
A 2024 systematic review and network meta-analysis (PMC12309109) searched PubMed, EMBASE, SCOPUS, and ClinicalTrials.gov up to August 2024, including 17 RCTs comparing turmeric preparations against placebo and active drug comparators (NSAIDs and acetaminophen) for knee osteoarthritis. 7
The headline finding was unambiguous: all turmeric preparations significantly reduced WOMAC pain scores compared to placebo. All three preparation types — conventional curcuminoid (CT), bioavailability-enhanced curcuminoid (BE), and polysaccharide preparations (PLS) — were effective. Bioavailability-enhanced preparations (BE) showed significant improvement in both WOMAC pain (MD −2.47; 95% CI: −3.27, −1.67) and WOMAC function (MD −9.62; 95% CI: −12.47, −6.76). Multiple head-to-head trials confirmed non-inferiority of curcumin versus NSAIDs: a 4-week multicentre study (n=367) found Curcuma domestica extract non-inferior to ibuprofen, with ibuprofen showing significantly higher gastrointestinal adverse events. The 2022 Frontiers meta-analysis confirmed curcumin equivalent to ibuprofen and diclofenac in joint pain and function improvement, but with a substantially lower adverse event incidence. Mechanistically, curcumin downregulates COX-2 mRNA while NSAIDs inhibit the COX-2 receptor — different points on the same pathway, producing comparable clinical effects with different side-effect profiles.
A 2023 meta-analysis specifically evaluating curcumin in rheumatoid arthritis (RA) pooled data from 6 RCTs comprising 539 patients with confirmed RA diagnosis. 8 Outcomes assessed included disease activity markers (DAS-28 disease activity score and ESR/erythrocyte sedimentation rate) and clinical joint findings (swollen joint count, tender joint count). The meta-analysis found significant improvements across all four outcome measures compared to control. DAS-28 is the most widely used clinical benchmark for RA disease activity — a composite score used by rheumatologists globally to determine disease severity and treatment response. Significant DAS-28 reduction in an RCT meta-analysis represents meaningful clinical validation. A 2024 RCT (Sedighi et al., European Journal of Nutrition) in SLE (systemic lupus erythematosus) patients further confirmed curcumin's anti-inflammatory efficacy in autoimmune inflammatory conditions. A broader 2025 PMC meta-analysis of curcumin in RA and SLE confirmed improvements in inflammatory biomarkers with curcumin, and noted that curcumin demonstrated effects comparable to ibuprofen and diclofenac without the common adverse effects reported with those drugs in comparison arms.
The landmark 1998 study by Shoba et al., published in Planta Medica, remains the foundational reference for curcumin bioavailability research and established the scientific basis for the curcumin-piperine combination that is now standard across the supplement industry. 3 The study measured plasma curcumin concentrations in human volunteers receiving either curcumin alone (2 g) or curcumin co-administered with piperine (20 mg). The curcumin + piperine group showed serum curcumin concentrations that were 2,000% higher than the curcumin-alone group (confirmed by HPLC), alongside increased bioavailability time and decreased elimination. The mechanism involves piperine's inhibition of hepatic and intestinal glucuronidation — the enzyme pathway that rapidly conjugates and inactivates curcumin — as well as reduction of intestinal drug efflux. A 2024 review (PMC11074217) of clinical bioavailability trials further documented that micelle formulations achieve up to 24× higher bioavailability than standard curcumin extract, and phospholipid complexes (such as Meriva) and lipid dispersions also achieve substantial improvements. The clinical implication is important: a curcumin supplement without a bioavailability enhancer may be substantially less effective than the clinical trial data suggests, since most positive trials used enhanced-bioavailability formulations. 4
The 2023 scoping review by Funk et al. (PMC10003109, Nutrients) is the most comprehensive overview of the curcumin clinical trial landscape, screening 9,528 publications to identify 389 citations meeting rigorous inclusion criteria. 9 The review analysed the distribution of clinical evidence across disease domains and found that joint/musculoskeletal conditions and metabolic disease represent the two most consistently and positively studied areas — with the strongest evidence clusters in osteoarthritis, rheumatoid arthritis, metabolic syndrome, and cardiometabolic risk factors. Importantly, the review noted that 55% of the US turmeric supplement market comprises enhanced-bioavailability formulations, and that approximately 45% of clinical trial citations used such enhanced formulations — reflecting growing recognition of the bioavailability challenge. The review also highlighted the emerging clinical trial data in depression, anxiety, and cognitive function, where curcumin's ability to cross the blood-brain barrier and modulate neurotrophic factor (BDNF) pathways has generated significant clinical interest. A complementary 2023 review (ACS Pharmacology & Translational Science) identified turmeric clinical evidence across 14 major chronic disease domains, with the strongest human trial evidence in arthritis, metabolic syndrome, and inflammatory bowel disease.
An important and sometimes overlooked dimension of turmeric research concerns the pharmacological difference between isolated curcumin and whole turmeric rhizome preparations — a distinction that directly reflects Ayurvedic formulation philosophy, which consistently used the whole plant rather than extracted compounds. A series of pre-clinical arthritis studies reviewed in Frontiers in Nutrition (2021) by Funk et al. compared turmeric rhizome extracts standardised for curcuminoid content, essential oil content, and the combined whole-rhizome extract. 6
The findings revealed that each fraction — curcuminoids and essential oils (turmerones) — had significant anti-arthritic effects independently, with the combined whole-rhizome extract showing additional activity attributable to polar compounds including polysaccharides. A pharmacokinetic study by Mahale et al. found that turmeric consumed at food-equivalent doses (analogous to daily dietary use in India) produced serum curcuminoid levels comparable to those from high-dose purified curcuminoid supplements formulated with bioavailability enhancers — suggesting that the traditional food use of whole turmeric with fat and pepper may be more bioavailable than previously recognised. This finding raises the significant possibility that the reductionist approach of studying isolated curcumin, while valuable mechanistically, may have underestimated the activity of traditional whole-turmeric preparations used as food — precisely the preparations used for 4,000 years in Ayurvedic medicine.
Clinical Evidence at a Glance — Pooled Meta-Analysis Findings
Traditional Use & Modern Dosage
Turmeric occupies the unique position of being both a daily food spice used at culinary doses and a therapeutic herb used at higher medicinal doses — a dual role validated by both traditional use and pharmacokinetic research showing that consistent dietary consumption can achieve meaningful plasma curcuminoid concentrations. Ayurvedic tradition prescribes it with fat (Sneha) and pungent herbs (Trikatu) for maximum absorption — both validated by modern bioavailability research. Milk is the classical medicinal vehicle (Ksheera Anupana), providing the fat necessary for absorption.
| Form | Traditional Preparation | Typical Dose / Use |
|---|---|---|
| Golden Milk (Haridra Ksheera) | ½–1 tsp turmeric powder in warm milk (or plant milk), with black pepper and ghee or coconut oil; the most classical medicinal preparation; the fat and pepper together maximise absorption | 1 cup once or twice daily; classical Rasayana preparation for respiratory health, immunity, and inflammation; closest modern equivalent to Ayurvedic kitchen medicine |
| Paste (Haridra Lepa) | Turmeric powder made into paste with water, ghee, or honey; applied topically to wounds, skin conditions, joints | Applied 2–3× daily; classical wound-healing, anti-inflammatory, and skin-brightening application; antibacterial properties support wound care |
| Churna (Powder) | Dried rhizome powder in warm water, honey, or ghee; classical oral medicinal form | 1–3 g (approximately ½–1 tsp) daily; combined with black pepper (⅛ tsp) to activate piperine bioavailability enhancement |
| Kvatha (Decoction) | Rhizome pieces or powder boiled in water with ginger and black pepper; classically used for inflammatory joint conditions and fever | 50–100 ml twice daily; add a few drops of sesame oil before drinking for fat-enhanced absorption |
| Standardised Extract + Piperine | Curcuminoid-standardised extract (typically 95% curcuminoids) combined with 5–20 mg piperine or equivalent bioavailability enhancer (phospholipid, micelle) | 500–1,500 mg standardised extract per day in divided doses; the form used in most positive clinical trials; essential to include a bioavailability enhancer for therapeutic plasma concentrations |
| Food (Culinary) Use | 1–2 tsp per meal in curries, rice, lentils; combined with oil, pepper, and heat — traditional Indian daily dietary use | Recent pharmacokinetic data suggests daily culinary consumption with fat and pepper may achieve serum curcuminoid levels comparable to enhanced-bioavailability supplements; the traditional dietary pattern may be more effective than previously recognised |
Supaveda Products with Haridra
Turmeric features across multiple Supaveda products — as a primary anti-inflammatory herb in joint and immunity formulas, and as part of the broader Rasayana complex in Supa Life:
Haridra is the cornerstone of SupaJoint — bringing its NF-κB inhibitory and COX-2/LOX-suppressing anti-inflammatory mechanisms directly to joint tissue, alongside chondroprotective action (MMP suppression, proteoglycan preservation) that extends beyond pain relief into cartilage protection. Formulated alongside Boswellia (Shallaki) — which directly inhibits 5-LOX through its boswellic acid fraction — and Ashwagandha — which reduces cortisol-driven systemic inflammation — the formula addresses joint inflammation from three distinct molecular pathways simultaneously. Black pepper extract (piperine) is included to maximise the 2,000% bioavailability enhancement validated in human pharmacokinetic studies.
In SupaImmune, Haridra contributes its Nrf2-activating antioxidant properties and immunomodulatory NF-κB inhibition — creating the anti-inflammatory foundation within which the immune-stimulating actions of Guduchi and Ashwagandha can operate without driving excessive inflammatory responses. Turmeric's role as Vishagni (destroyer of inflammatory "poisons") is most precisely expressed in this formulation context: reducing the chronic low-grade inflammatory burden that impairs immune cell function and increases susceptibility to acute infection.
In classical Chyawanprash formulations, Haridra serves as the primary anti-inflammatory and detoxifying herb — its Vishagni action providing the systemic anti-inflammatory substrate within which the Rasayana herbs build and strengthen tissues. In Supa Life, turmeric's daily food-level dosing is amplified by the fat base (ghee equivalent in the preserve form) that enhances curcumin absorption — mirroring the classical cooking practice of adding turmeric to oil-based preparations that Ayurvedic physicians discovered maximised its biological availability long before liposome science was conceived.
Safety & Precautions
Turmeric has been consumed daily as a food spice by hundreds of millions of people for thousands of years and has an outstanding safety record at culinary doses. Therapeutic supplementation (500–1,500 mg standardised extract daily) has been well-tolerated in clinical trials of up to 4–6 months duration, with side effects characterised as mild and self-limiting. The 2023 scoping review of 389 clinical trials (PMC10003109) confirmed a generally good safety profile across the clinical evidence base. 9
Please Note
- Pregnancy: Turmeric at culinary/food doses is safe and widely consumed during pregnancy in India. At therapeutic supplementation doses (standardised extracts 500 mg+), turmeric has emmenagogue and mild uterine-stimulating properties. High-dose supplementation should be avoided during pregnancy without professional guidance. Food amounts remain appropriate.
- Blood thinners and antiplatelet drugs: Curcumin has anti-platelet and mild anticoagulant properties — confirmed in clinical studies. Those on warfarin, aspirin, clopidogrel, or other anticoagulants should inform their prescribing physician and monitor for additive effects. Consistent daily intake is preferable to erratic high-dose use.
- Iron absorption: Curcumin chelates iron in the gut. Those with iron-deficiency anaemia or on iron supplements should take turmeric and iron preparations at least 2 hours apart. Food-level consumption with iron-rich meals should be moderated.
- Gallstones and bile duct obstruction: Turmeric strongly stimulates bile secretion — a property that is beneficial for liver and digestion in most people, but contraindicated in confirmed gallstone obstruction or bile duct blockage. Those with known gallstones should consult a healthcare provider before therapeutic supplementation.
- High-Pitta constitutions: Turmeric's heating (Ushna) potency can aggravate Pitta in susceptible individuals — causing heartburn, acid reflux, or skin heat. Those with active Pitta excess (GERD, inflammatory skin conditions, excess heat) should use turmeric with cooling carriers: coconut milk, ghee, aloe vera, or with a pinch of cardamom to temper the heat.
- Drug interactions: Piperine (the bioavailability enhancer) is a potent inhibitor of CYP3A4 and P-glycoprotein drug metabolism pathways and can significantly alter the plasma levels of many pharmaceutical drugs. Those on multiple medications should seek pharmacy advice before beginning piperine-containing supplements.
- GI sensitivity: High doses (2 g+) of curcumin may cause mild nausea, loose stools, or gastric discomfort in sensitive individuals. Start at lower doses and increase gradually. These effects are self-limiting and resolve on dose reduction.
Key Takeaways
Evidence-backed bullet points:
20,000+ PubMed publications and 400+ completed clinical trials — turmeric is the most studied botanical in the history of medical science, and the best-selling botanical supplement in the United States
Curcumin directly inhibits NF-κB — the master "inflammation switch" transcription factor that controls 200+ inflammatory genes. This single upstream target explains its broad anti-inflammatory activity across arthritis, metabolic disease, cardiovascular, and neurological conditions
Adding black pepper increases curcumin absorption by 2,000% — confirmed in human pharmacokinetic study (Shoba et al., 1998, Planta Medica). Ayurvedic formulation practice was combining turmeric with Trikatu (which includes black pepper) for this exact reason for centuries before the biochemistry was described
Non-inferior to ibuprofen for knee osteoarthritis — confirmed in a multicenter trial (n=367) and multiple meta-analyses; all 17 turmeric preparations in a 2024 network meta-analysis significantly reduced WOMAC pain vs placebo. With fewer gastrointestinal adverse events than NSAIDs
Meta-analysis of RCTs (Frontiers 2025 umbrella review): significant reductions in CRP, TNF-α, and IL-6 — the three canonical clinical markers of systemic inflammation — confirmed across pooled meta-analyses of randomised controlled trials vs placebo
Confirmed effective in rheumatoid arthritis: meta-analysis of 6 RCTs (539 patients) showed significant improvements in DAS-28 disease activity score, ESR, swollen joint count, and tender joint count — the primary clinical benchmarks used by rheumatologists
Simultaneously inhibits COX-2 and 5-LOX — two separate inflammatory enzyme pathways. NSAIDs inhibit only COX pathways; curcumin inhibits both, providing broader anti-inflammatory coverage through a dual-pathway mechanism unavailable to any single NSAID
Traditional cooking with fat and pepper may be more effective than previously recognised: a pharmacokinetic study found that turmeric consumed at Indian dietary doses with oil and pepper achieved serum curcuminoid levels comparable to enhanced-bioavailability supplements — validating 4,000 years of Ayurvedic kitchen medicine
Curcumin crosses the blood-brain barrier and modulates BDNF (brain-derived neurotrophic factor), amyloid-β aggregation, tau protein, serotonin, and dopamine — generating growing clinical trial evidence in depression, anxiety, and cognitive protection
Outstanding safety record at culinary and therapeutic doses; mild GI effects at high doses are self-limiting. Key precautions: avoid high-dose supplementation in pregnancy; inform GP if on anticoagulants; separate from iron supplements by 2 hours; piperine interacts with drug-metabolising enzymes
References
- Kunnumakkara, A.B., Hegde, M., Girisa, S., Kumar, A., Daimary, U.D. et al. (2023) 'Role of turmeric and curcumin in prevention and treatment of chronic diseases: lessons learned from clinical trials', ACS Pharmacology & Translational Science, 6(4), pp.447–518. doi: 10.1021/acsptsci.2c00012. PMC10111629. [Primary comprehensive clinical trial review; 20,000+ curcumin PubMed citations; 400+ clinical trials; 250+ molecular targets; 14 chronic disease domains; whole turmeric vs isolated curcumin evidence; Vishagni Sanskrit classification; 4,000-year traditional use history; best-selling US botanical status].
- Jafari, M. et al. (2025) 'Curcumin and multiple health outcomes: critical umbrella review of intervention meta-analyses', Frontiers in Pharmacology, 16. PMC12176752. doi: 10.3389/fphar.2025.1601204. [Umbrella review of 6 meta-analyses of RCTs; CRP reduction WMD −0.58 mg/L (95% CI: −0.74, −0.41); TNF-α reduction WMD −3.48 pg/mL (95% CI: −4.38, −2.58); IL-6 reduction WMD −1.31 pg/mL (95% CI: −1.58, −0.67); body weight WMD −0.82 kg; BMI −0.30 kg/m²; waist circumference −1.31 cm; adiponectin increase; VCAM-1 and FMD endothelial improvements; antidiabetic properties summary].
- Shoba, G., Joy, D., Joseph, T., Majeed, M., Rajendran, R. and Srinivas, P.S. (1998) 'Influence of piperine on the pharmacokinetics of curcumin in animals and human volunteers', Planta Medica, 64(4), pp.353–356. doi: 10.1055/s-2006-957450. PMID: 9619120. [Landmark bioavailability study; 2,000% increase in human serum curcumin concentration with 20 mg piperine co-administration; mechanism: inhibition of hepatic and intestinal glucuronidation, reduced intestinal efflux; pharmacokinetic validation of Ayurvedic Trikatu formulation principle].
- Bagban, I.M., Srivastava, S., Jain, A. and Bhatt, P.C. (2024) 'Clinical trials on curcumin in relation to its bioavailability and effect on malignant diseases: critical analysis', European Journal of Clinical Pharmacology, 80. PMC11074217. doi: 10.1007/s00228-023-03590-1. Also: Hewlings, S.J. and Kalman, D.S. (2017) 'Curcumin: a review of its effects on human health', Foods, 6(10), p.92. PMC5664031. [Micelle formulation 24× higher bioavailability (Turmipure GOLD™); piperine mechanism: glucuronidation inhibition; phospholipid complex BCM-95; clinical bioavailability enhancement overview; NF-κB inhibition confirmed in pancreatic cancer trial tissue; 2,000% piperine enhancement validated; lipid carriers overview].
- Prasad, S. and Aggarwal, B.B. (2011) 'Turmeric, the golden spice: from traditional medicine to modern medicine', in Benzie, I.F.F. and Wachtel-Galor, S. (eds) Herbal Medicine: Biomolecular and Clinical Aspects, 2nd edn. Boca Raton, FL: CRC Press/Taylor & Francis. [Haridra Sanskrit name and etymology; Vishagni (destroyer of poisons) classification; Kanchani, Nisha, Gauri, Rajani synonyms; classical Charaka Samhita and Sushruta Samhita references; Chinese Jiang Huang application; Siddha Kaya Kalpa classification; 4,000-year Ayurvedic documentation; traditional dosage and preparation forms].
- Funk, J.L., Morin, A., Rubin, R. and Frye, J.B. (2021) 'Perspective on improving the relevance, rigor, and reproducibility of botanical clinical trials: lessons learned from turmeric trials', Frontiers in Nutrition, 8, p.782912. doi: 10.3389/fnut.2021.782912. [Whole turmeric vs isolated curcumin evidence; turmerone essential oils independent anti-arthritic activity; polysaccharide fraction anti-arthritic effects; Mahale et al. pharmacokinetic study — dietary dose equivalent serum levels; curcuminoid + essential oil + polysaccharide synergy; whole-rhizome superior to reductionist extracts in some contexts].
- Wongcharoen, W. and Phrommintikul, A. (2025) 'Effect of turmeric products on knee osteoarthritis: a systematic review and network meta-analysis', BMC Musculoskeletal Disorders (PMC12309109). doi: (August 2024 search). [Network meta-analysis; 17 RCTs; all turmeric preparations significantly reduced WOMAC pain; BE preparations: WOMAC pain MD −2.47 (95% CI −3.27, −1.67); WOMAC function MD −9.62 (95% CI −12.47, −6.76); conventional CT: WOMAC pain MD −3.17; comparison with NSAIDs (diclofenac, ibuprofen, acetaminophen); COX-2 mRNA downregulation mechanism vs NSAID COX-2 receptor inhibition; Kuptniratsaikul multicenter n=367 non-inferiority vs ibuprofen].
- Mousavi, S.M. et al. (2025) 'Effects of curcumin and Curcuma longa extract on inflammatory biomarkers in patients with rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE): a systematic review and meta-analysis of randomized controlled trials', BMC Rheumatology. PMC12696035. [Meta-analysis 6 RCTs; 539 RA patients; significant DAS-28, ESR, swollen joint count, tender joint count improvements; curcumin effects comparable to ibuprofen and diclofenac without common adverse effects; SLE Sedighi et al. 2024 RCT (Eur J Nutr); IBD, OA, psoriasis, and autoimmune efficacy summary].
- Panknin, T.M., Howe, C.L., Hauer, M., Bucchireddigari, B., Rossi, A.M. and Funk, J.L. (2023) 'Curcumin supplementation and human disease: a scoping review of clinical trials', Nutrients, 15(3), p.739. PMC10003109. doi: 10.3390/nu15030739. [Scoping review; 9,528 initial → 389 meeting criteria; joint/musculoskeletal and metabolic disease strongest evidence clusters; 55% US market enhanced bioavailability formulations; 45% trials used enhanced bioavailability products; emerging depression/cognition/BDNF clinical trial data; safety profile overview; Kunnumakkara et al. 2023 identified 148 turmeric clinical trial references].
- Dehzad, M.J., Ghalandari, H., Nouri, M. and Askarpour, M. (2023) 'Antioxidant and anti-inflammatory effects of curcumin/turmeric supplementation in adults: a GRADE-assessed systematic review and dose-response meta-analysis of randomized controlled trials', Cytokine, 164, p.156144. doi: 10.1016/j.cyto.2023.156144. PMID: 36804260. [GRADE-assessed meta-analysis; databases PubMed, Scopus, Web of Science, Cochrane, Google Scholar to October 2022; CRP, TNF-α, IL-6, IL-1β primary outcomes; TAC, MDA, SOD oxidative stress markers; dose-response analysis; significant SOD increase and MDA reduction vs placebo].